The vision is to help oncologists to select peptides that can be used in a personalized peptide vaccine. There are many inefficency, as well as economical and medical roadblocks in the process that leads to FDA's market authorisation. If oncologists were able to define vaccines in the off label legal framework, lot of people would be helped.
Switch branches/tags
Nothing to show
Clone or download
Fetching latest commit…
Cannot retrieve the latest commit at this time.
Permalink
Type Name Latest commit message Commit time
Failed to load latest commit information.
Blast.php
ConfigFile.php
Controller.php
CoversHLA.php
Efficient.php
Faq.html
Immunogenicity.php
LICENSE
MetGene.php
MetTsa.php
MngInputErrs.php
MngUserParams.php
MutSequence.php
Mutations.php
NetMHCAnswer.php
NetMHCMain.php
NetMHCUtils.php
NoHLA.php
ProtSeq.php
Publish.php
README.md
Uniprot.php
index.html
molecule.jpg

README.md

The vision is to help oncologists to find and select peptides that can be used in a personalized peptide vaccine. It is a work in progress.

There are many inefficency, as well as economical and medical roadblocks in the process that leads to FDA's market authorisation. If oncologists (or their health providers) were able to define vaccines in the off label legal framework, lot of people would be helped.

We focus here on peptide vaccines, because while most clinical results using peptide vaccines have been disappointing, a peptide vaccine with appropriate adjuvants is easy to produce, low cost and probably one the easier strategies to induce tumor-reactive T cells in people with still a good health. Economically, it makes sense.

But peptide vaccines can be dangerous too. Roadmap: Our peptide designs aimed at : ...Do not induce anaphylaxis (no B cell epitopes) ...If possible beeing promiscuous (bind to more than one MHC allele) ...Being both CD4 and CD8 epitopes (for efficiency) ...Being oligomeric (looking roughly like a retroviral capsid) ...Having amphilicity (as viruses) ...Having post-transcriptional modifications fully specified (to standardize production) ...Tailored for intravenous injection

The service is designed to be easy to use and has only a few simple parameters: It infers a seed for the simulated proteolysis mechanism either from a specific protein tumor marker, or uses a gene and its mutation. It uses NetMHCpan as well as Uniprot and VaxiJen. If NetMHCpan is unable to create a short list of peptides, it generates its own. The output presents several candidate peptides with various profiles (best fit for a given HLA, most immunogenicity, etc..).

Note that neither the safety nor the efficacy of the peptides suggested by this tool can be guaranteed.

Also note that this tool still has very limited functionality and that it still is in alpha testing.